Complex Synthesis

While our core Small Molecules technologies concern the development and manufacture of chiral synthons, we also have developed extensive capability in the multi-step synthesis of APIs and advanced pharmaceutical intermediates requiring complex chemistry. If you have a difficult synthetic challenge, where our capabilities can provide you with a clear, sustainable advantage, please contact us.

Learn more about complex synthesis at Dowpharma^SM:

Complex Synthesis: Travoprost (54KB PDF)
Development Increases Yield in Alkaloid Synthesis (32KB PDF)

In order to view some information you may need to download Adobe Reader.

^SMService mark of The Dow Chemical Company


Capabilities and Services Biocatalysis Biocatalysis Capability Collaborators Enzyme Classes Chemocatalysis Asymmetric Hydrogenation Hydroformylation Trost Allylic Alkylation Complex Synthesis Products Offered Process Development Customer Needs Development Timeline Emerging Pharma Catalyst/Ligand Availability Unnatural Fmoc Amino Acids Unnatural Boc Amino Acids 2-Alkyl Succinates Amines Alcohols Functionalized Cyclopentanes Scaffolds Facilities Literature and Resources Asymmetric Hydrogenation Dowpharma Scientific Publications Hydroformylation Trost Allylic Alkylation Complex Synthesis Biocatalysis Process Development General Publications News Center Source: Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with Dowpharma<sup>SM</sup> Contract Manufacturing Services. Dowpharma Relaunches Web Site, Will Make Donation to UNICEF Dow Expands Presence in Pharmaceutical Market, Uniting Existing Offers Under Dowpharma Portfolio Dowpharma Announces New Capabilities in Asymmetric Hydroformylation for Pharmaceutical Applications License of JST Catalyst Technology Expands Dowpharma’s Chiral Commercial Production Capabilities Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan Events Calendar Contact Us	Complex Synthesis While our core Small Molecules technologies concern the development and manufacture of chiral synthons, we also have developed extensive capability in the multi-step synthesis of APIs and advanced pharmaceutical intermediates requiring complex chemistry. If you have a difficult synthetic challenge, where our capabilities can provide you with a clear, sustainable advantage, please contact us. Learn more about complex synthesis at Dowpharma^SM: Complex Synthesis: Travoprost (54KB PDF) Development Increases Yield in Alkaloid Synthesis (32KB PDF) In order to view some information you may need to download Adobe Reader. ^SMService mark of The Dow Chemical Company
	Small Molecules Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved.